Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy

Table 2 CMR Imaging assessment of left atrial volumes and function in sarcomere gene mutation carriers with and without left ventricular hypertrophy compared to healthy family members

	G+/LVH+ Overt HCM (N = 34)	G+/LVH- Preclinical (N = 24)	G−/LVH- Controls (N = 15)	P-value overall*	P-value* Preclinical vs Control	P-value* HCM vs Preclinical	P-value* HCM vs Control
LAV Max/BSA, ml/m²	46 ± 18	32 ± 12	33 ± 9	0.031	0.83	0.050	0.13
LAV BAC/BSA, ml/m²	31 ± 16	20 ± 9	18 ± 6	0.015	0.56	0.050	0.10
LAV Min/BSA, ml/m²	20 ± 12	12 ± 5	10 ± 4	0.019	0.20	0.047	0.12
LAPEmF, %	35 ± 11	41 ± 11	47 ± 9	0.002	0.077	0.23	0.006
LAAEmF, %	38 ± 11	39 ± 5	43 ± 9	0.033	0.060	0.46	0.074
LATEmF, %	59 ± 10	64 ± 8	70 ± 7	<0.001	0.002	0.20	0.005

LVH was based on echocardiographic core laboratory measurements, defined as a maximal LV wall thickness (LVWT) ≥12 mm in adults or a z-score ≥ 3 in participants <18 years of age. LAV left atrial volume, BAC before atrial contraction, BSA body surface area, LATEmF Total left atrial function, LAPEmF left atrial passive function, LAAEmF left atrial active function. Values represent mean and SD unless otherwise indicated
*Adjusted for age, gender, BSA and family relationships; P values ≤0.017 were considered to indicate statistical significance, applying Bonferroni correction for multiple comparisons across the three groups

ISSN: 1532-429X